← Back to Clinical Trials
Recruiting Phase 4 NCT07132515
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
◆ AI Clinical Summary
Plain-language summary for patients
Trial Parameters
Condition Cirrhosis
Sponsor Mansoura University
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 100
Sex ALL
Min Age 18 Years
Max Age 70 Years
Start Date 2023-08-15
Completion 2025-08
All Conditions
Interventions
Enoxaparin, warfarrin, or apixaban
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
We will give an anticoagulant against portal vein thrombosis, and watch for the results.
Eligibility Criteria
Inclusion Criteria: * Portal vein thrombosis, Cirrhosis, With or without HCC, Child A \& B Exclusion Criteria: * Platelets\<10000, Createnine \>1.9, Budd ciarri, Uncontrolled active bleeding
Related Trials
NCT05484206
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
View Trial →
NCT06863012
EUS-guided Portal Pressure Gradient (PPG) Measurement: a Potential Alternative to the Traditional HV
View Trial →
NCT06937307
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney I
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology